Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 12/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10156594 | 1.00 | EPHX2 (0.61) | EPHX2EPHX1KDM4EALDH1A1NPC1 | |
| SCHEMBL9003951 | 0.89 | EPHX2 (0.50) | EPHX2EPHX1KDM4EALDH1A1NPC1 | |
| SCHEMBL9547538 | 0.86 | EPHX2 (0.78) | EPHX2EPHX1KDM4EALDH1A1NPC1 | |
| SCHEMBL3273214 | 0.82 | POLB (0.41) | EPHX2EPHX1KDM4EALDH1A1NPC1 | |
| SCHEMBL3273218 | 0.82 | POLB (0.41) | EPHX2EPHX1KDM4EALDH1A1NPC1 | |
| SCHEMBL15765690 | 0.82 | ATM (0.48) | EPHX2EPHX1KDM4EALDH1A1NPC1 | |
| SCHEMBL15388389 | 0.82 | POLB (0.41) | EPHX2EPHX1KDM4EALDH1A1NPC1 | |
| SCHEMBL10245502 | 0.82 | ATM (0.48) | EPHX2EPHX1KDM4EALDH1A1NPC1 | |
| SCHEMBL21452802 | 0.82 | ATM (0.48) | EPHX2EPHX1KDM4EALDH1A1NPC1 | |
| SCHEMBL10155582 | 0.81 | EPHX2 (0.56) | EPHX2EPHX1KDM4EALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188100-B2 | Adenosine derivatives as A2A receptor agonists | NOVARTIS AG (CH) | 2012-05-29 | — | — | US | disclosed |
| EP-2066669-B1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20090325967-A1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| EP-1903044-A1 | Adenosine Derivatives as A2A Receptor Agonists | Novartis AG (CH) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325967-A1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | ADORA2A, ADORA2B, ADORA1 | EPHX2 1537/4885EPHX1 1870/4885KDM4E 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.